More major companies will be reporting their earnings before opening bell on Wednesday, including Dr Pepper Snapple Group Inc. (NYSE:DPS), Credit Suisse Group AG (NYSE:CS), Corning Incorporated (NYSE:GLW), Elan Corporation, plc (NYSE:ELN) and Eli Lilly & Co. (NYSE:LLY).
Dr Pepper Snapple Group Inc. (NYSE:DPS) is expected to report first-quarter earnings per share of 46 cents on revenue of $1.4 billion, according to a Bloomberg consensus. The company’s earnings surprised to the negative last quarter and in the first quarter of 2012. However, Dr Pepper Snapple Group Inc. (NYSE:DPS) did meet Bloomberg’s revenue expectations for the two quarters.
Analysts are expecting Credit Suisse Group AG (NYSE:CS) to report revenue of 7 billion Swiss francs. The bank missed fourth quarter revenue expectations. The banking industry as a whole has been struggling and eliminating jobs by the thousands. Credit Suisse Group AG (NYSE:CS) said last month it would stop taking new stakes in hedge funds as it moves to comply with stricter regulations on how banks manage their capital and risks.
Expectations for Corning Incorporated (NYSE:GLW) indicate a consensus of 24 cents per share in earnings on revenue of $2 billion. That’s compared to last quarter’s 34 cents per share on $2.1 billion in revenue and 30 cents per share on $1.9 billion in revenue in the same quarter a year ago. Corning Incorporated (NYSE:GLW) surprised to the positive in earnings and met consensus for revenue in both previous quarters.
Analysts are looking for Elan Corporation, plc (NYSE:ELN) to report earnings per share of 3 cents on revenue of $1.41 million. That’s a significant decline from the company’s posted first-quarter revenue of 2012, which was $288 million. The company’s last four quarterly reports were near to, or met the consensus of analysts polled by Bloomberg.
Eli Lilly & Co. (NYSE:LLY) is expected to report earnings per share of $1.05 on revenue of $5.7 billion, according to a consensus of analysts polled by Bloomberg. That’s compared to 92 cents in earnings per share on $5.6 billion in revenue in the same quarter a year ago. The drug maker surprised to the positive by more than 15 percent in earnings per share during the first quarter of 2012. It surprised again by almost 8 percent in the last quarter of 2012. Revenues for both previous quarters also surprised analysts slightly.
